Joins from biotechnology firm Biogen Idec
US contract pharmaceutical manufacturer and developer of dosage forms Patheon has appointed James Mullen as chief executive. Mullen has also joined Patheonís board of directors.
Mullen was most recently ceo and president at biotechnology firm Biogen Idec, formed from the merger, led Mullen, of Biogen and Idec Pharmaceuticals. Prior to the merger, Mullen was ceo and president of Biogen from 2000 to 2002, and chairman, ceo and president until 2003. Prior to that, he held various operating positions at Biogen, including vice president, Operations.
Peter Bigelow, Patheonís president of North American Operations, had been acting as interim ceo while the search for the new ceo was conducted.